Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage
To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.
A phase III prospective pragmatic double blind randomised placebo controlled trial
Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham
Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian
Dr Matt Reed is the local contact for recruitment of ED patients into the study.
Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.
For more information please refer to main trial website
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)